Some diseases are liable to be as dependent on one Bcl-2 protein as CLL; the majority of tumors will likely require combinations of these drugs to have a significant therapeutic impact; however, these combinations may show unacceptable toxicity [190,191,192,193,194,195,196,197,198,199,200,201]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.